Clinical Trial Update: Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma [Phase 2]

View source ↗

Summary

A Phase 2 single-dose study assessed the safety and efficacy of S-1226 (8%) in subjects with mild atopic asthma; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• S-1226 (8%) (S-1226)

Snippet

Sponsor: SolAeroMed Inc. | Conditions: Asthma | Phase 2 | Status: COMPLETED